Navigation Links
Organogenesis Receives Two Prestigious Awards for Economic Impact and Manufacturing Excellence
Date:12/1/2008

CANTON, Mass., Dec. 1 /PRNewswire/ -- Organogenesis, Inc., a leading regenerative medicine company, has just been named the recipient of two prestigious awards honoring the company's cutting edge development, manufacturing and economic impact.

Organogenesis' manufacturing division has been named 2008 "Team of the Year" by Pharmaceutical Manufacturing, a prominent industry publication. The "Team of the Year" honor will be highlighted in the magazine's upcoming December 2008 issue. Additionally, the company was honored by the Massachusetts Alliance for Economic Development as the Silver winner of its Fifth Annual Team Massachusetts Economic Impact Award, presented at a November 25th awards event.

Organogenesis was the first company to successfully mass produce living regenerative medicine products -- reaching hundreds of thousands of patients in the U.S. and around the world. Its signature product, Apligraf(R), is the first living cell therapy to have received U.S. Food and Drug Administration (FDA) approvals to close both diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs).

"We are honored to receive national and state recognition of the company's vision, its ingenuity and hard work," said Geoff MacKay, CEO of Organogenesis. "Organogenesis is committed to bringing the promise of regenerative medicine into everyday medical care. To have our efforts and hard work recognized in this way is very gratifying for the company and our employees."

MacKay continued, "The intricate processes required to mass produce a living cell therapy product require a great deal of innovation and dedication, and our top-notch manufacturing group hits its target every day. This team is in large part responsible for the quality, the growth and the contribution that marks Organogenesis as a regenerative medicine leader in Massachusetts and around the world."

Award Recognizes Manufacturing E
'/>"/>

SOURCE Organogenesis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Organogenesis Names Regenerative Medicine Expert Dr. Damien Bates Vice President, Medical Affairs
2. Actavis Receives Approval of Generic Wellbutrin XL(R) 150mg in the U.S.
3. Watson Pharmaceuticals Receives FDA Final Approval for Generic Wellbutrin XL(R) 150 mg
4. EpiVax Receives NIH Grant for $390,000 to Optimize HIV Vaccine Delivery
5. Melissa Murer Corrigan Receives Prestigious NOCA Leadership Award
6. ECO2 Plastics, Inc. Receives Favorable FDA Opinion Letter Approving the Use of Its Recycled Plastic Flake in Food Packaging Applications
7. Lilly Receives NCQA Health Information Product Certification for Interactive Online Health Education Answers Program
8. Cepheid Receives Health Canada License for First Molecular Diagnostic Test for MRSA and S. aureus Soft Tissue Infections
9. Accordia Global Health Foundation Receives $12.5 Million Grant From Bill & Melinda Gates Foundation
10. Jon M. Huntsman Receives American Cancer Society Medal of Honor
11. Keryx Biopharmaceuticals Receives Nasdaq Notification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/4/2009)...pain and injury, doctors say , , SATURDA...re not as young as they used to be, exercise is ju...re in order to stay injury-free. , "As boome...emselves from injuries when exercising," Dr. Ray M...opaedic Surgeons, said in a news release. "A littl...
(Date:7/3/2009)...se service excellence during National Customer Ser... London (PRWeb UK) July 3, 2009 -- Companies and...o celebrate the importance of excellent customer s... Week - 5-11 October., , ,Employers in all sectors... local authority see the week, which is organised ...
(Date:7/3/2009)... middle age may triple the risk, study shows , ...le-aged adults who live alone are twice as likely ...n life compared to those who are married or live w...among those who are divorced or widowed, according.... , The study included 2,000 men and women in F...
(Date:7/3/2009)...- Sundia MediTech, a leading,integrated pharmaceu...hanghai,China announced today that Dr. Chen Chen...istry Services. , Prior to joining Sundia, ...,discovery and development company in San Diego, U... Director of Medicinal Chemistry of Neurocrine. I...
Breaking Medicine News(10 mins):Health News:Exercise Tips to Keep Boomers on Their Feet 2Health News:Businesses Urged to Sign Up and Celebrate Customer Service 2Health News:Living Alone Increases Odds of Developing Dementia 2Health News:Sundia MediTech Appoints Dr. Chen Chen as Senior VP of Chemistry 2
...ase suffered more complications if they tried doin...tudied a group of 200 patients with chronic obstru...igh dose of inhaled steroids, to manage their cond...ime, they either continued the steroids or receive...
...s of C-reactive protein and low levels of albumin ...ents. Of the 25% of patients who die while on kidn...ious studies suggest that such patients run betwee...rt problems compared to the rest of the population...
...a major factor accounting for differences in life ...own that black people live, on average, six years ...lete //high school are at a similar disadvantage c...rst time, a study has identified the major health ...
...c events in Asian people at risk.Coronary artery d...outh Asian people, especially if they move to the ...ained by conventional risk factors,// like diabete...rs in India and Israel have been experimenting wit...
Other Medicine News:
(Date:6/26/2009)...ndia,s Breast Cancer Recurrence Test MammaPrint,I...us Recommendations" issued,on 23 Jun 2009 12:00 G...vised,that the subheadline was missing from the r... Complete, corrected release follows: , ,... Recurrence Test MammaPrint Included in,Internati...
(Date:6/25/2009)...xperts Slated to Attend First National Symposium -...e first national symposium designed to explore the... week in New York City when thirteen top experts g...respective fields. The SUNY Youth Sports Institut...th impacts that the $5 billion-a-year energy drink...
(Date:6/25/2009)...Covering ARIKACE for Once-Daily Treatment of Pseud....J., June 25 Cystic Fibrosis Found...f the Cystic Fibrosis Foundation, has provided a $...ued development of ARIKACE(TM) (liposomal amikacin... Pseudomonas lung infections in cystic fibrosis ...
(Date:6/24/2009)... , - Recruitment o...on-Surgical Treatment of Eye Disease With No Repor...ext Brussels: THR), a biotechnology company,focus...treatments for eye,disease, vascular disease and ...roplasmin, which is in Phase III trials for the tr...
Breaking Medicine Technology:/C O R R E C T I O N -- Agendia B.V./ 2/C O R R E C T I O N -- Agendia B.V./ 3SUNY Youth Sports Institute Convenes Top Experts in NYC Next Week to Present Research & Analysis on Energy Drink Health Impacts 2SUNY Youth Sports Institute Convenes Top Experts in NYC Next Week to Present Research & Analysis on Energy Drink Health Impacts 3SUNY Youth Sports Institute Convenes Top Experts in NYC Next Week to Present Research & Analysis on Energy Drink Health Impacts 4Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM) 2Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM) 3Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM) 4ThromboGenics' Microplasmin Phase III Program Progressing According to Schedule 2ThromboGenics' Microplasmin Phase III Program Progressing According to Schedule 3Genetic Engineering 26 Biotechnology News reports on advances in miRNA 3639 1Catholic Healthcare West and SEIU Begin Negotiations for 15 000 Hospital Workers 13193 1Catholic Healthcare West and SEIU Begin Negotiations for 15 000 Hospital Workers 13193 2Federal District Court Ruling Holding Illinois Parental Notice of Abortion Act of 1995 Unconstitutional 13191 1What are the Odds 3F Friends Give Birth to Leap Year Babies within Hours of Each Other 13188 1
...8, 2007 /PRNewswire-FirstCall/ --,Viragen, Inc. an...lts from a sponsored in vitro study conducted at U...ron(R) (multi-,subtype, human alpha interferon) su...lones to a far greater degree than,recombinant alp...lication in AntiCancer Research, International Jou...
...SINESS WIRE)--May 8, 2007 - AVANIR,Pharmaceuticals...he,efficacy, safety and improvements in patient-ce...al neuropathic (DPN) pain treated,with the investi...dine) will be presented in two scientific posters ...c Pain, being held in,Berlin, Germany on June 7 to...
Other Medicine Technology:Multiferon Shows Potent Activity in Preventing the Progression of,Malignant Melanoma; Study to be Published 2Multiferon Shows Potent Activity in Preventing the Progression of,Malignant Melanoma; Study to be Published 3Multiferon Shows Potent Activity in Preventing the Progression of,Malignant Melanoma; Study to be Published 4AVANIR Pharmaceuticals to Present Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at Second International Congress on,Neuropathic Pain 2AVANIR Pharmaceuticals to Present Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at Second International Congress on,Neuropathic Pain 3AVANIR Pharmaceuticals to Present Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at Second International Congress on,Neuropathic Pain 4
... Angiotensin Converting Enzyme (ACE), also known a...C 3.4.15.1) with a molecular weight of at least 12...single polypeptide chain, a polysaccharide residue... cell types such as neuronal cells and renal proxi...
Vitamin B6 REA Vitamin Assays, Cardiovascular 001-RK-VB6
Myoglobin RIA Lipid / Protein Quantification, Cardiovascular 024-IDC-11 Muscle Disease
Anti-Gliadin IgA (Ab) EIA Gastrointestinal Markers 027-GD17 Celiac Disease Food Allergy
Medicine Products: